You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Alembic Pharma rises after zero observations from USFDA

Capital Market 

Shares of the pharmaceutical company rose 2.04% to Rs 520.75 after a successful USFDA inspection at the company's Vadodara facility.

Alembic Pharmaceuticals announced after market hours yesterday, 20 August 2019, that its bioequivalence facility in Vadodara, Gujarat was inspected by US Food & Drug Administration (USFDA) between 12th and 16th August 2019 and between 12th and 20th August 2019 for bioequivalence bioanalytical and bioequivalence clinical. There were no 483s issued by USFDA at the end of the inspection.

483 is a form used by the FDA to document and communicate concerns discovered during its inspections.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, August 21 2019. 11:44 IST